[go: up one dir, main page]

AU2001295671A1 - Pharmaceutical composition for immunisation against aids - Google Patents

Pharmaceutical composition for immunisation against aids

Info

Publication number
AU2001295671A1
AU2001295671A1 AU2001295671A AU9567101A AU2001295671A1 AU 2001295671 A1 AU2001295671 A1 AU 2001295671A1 AU 2001295671 A AU2001295671 A AU 2001295671A AU 9567101 A AU9567101 A AU 9567101A AU 2001295671 A1 AU2001295671 A1 AU 2001295671A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
against aids
immunisation against
composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295671A
Inventor
Francois Dalencon
Jean Haensler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Publication of AU2001295671A1 publication Critical patent/AU2001295671A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

The invention relates to the field of pharmaceutical compositions for use in immunization against HIV-related infections, and concerns a pharmaceutical composition comprising at least an HIV antigen and DCchol. Such a composition has proved to be particularly interesting for inducing through the mucus system IgG and IgA specific to the administered antigen. The inventive pharmaceutical composition, in a particularly advantageous manner, can be in the form of a liposome suspension or emulsion.
AU2001295671A 2000-10-06 2001-10-08 Pharmaceutical composition for immunisation against aids Abandoned AU2001295671A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (en) 2000-10-06 2000-10-06 VACCINE COMPOSITION
FR00/12808 2000-10-06
PCT/FR2001/003096 WO2002028427A2 (en) 2000-10-06 2001-10-08 Pharmaceutical composition for immunisation against aids

Publications (1)

Publication Number Publication Date
AU2001295671A1 true AU2001295671A1 (en) 2002-04-15

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001295671A Abandoned AU2001295671A1 (en) 2000-10-06 2001-10-08 Pharmaceutical composition for immunisation against aids
AU2001295673A Abandoned AU2001295673A1 (en) 2000-10-06 2001-10-08 Vaccine composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001295673A Abandoned AU2001295673A1 (en) 2000-10-06 2001-10-08 Vaccine composition

Country Status (12)

Country Link
US (3) US20030190326A1 (en)
EP (2) EP1326635B1 (en)
AT (2) ATE350057T1 (en)
AU (2) AU2001295671A1 (en)
CA (1) CA2424836A1 (en)
CY (1) CY1105943T1 (en)
DE (2) DE60110822T2 (en)
DK (1) DK1326636T3 (en)
ES (2) ES2275738T3 (en)
FR (1) FR2814958B1 (en)
PT (2) PT1326635E (en)
WO (2) WO2002028428A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE335510T1 (en) * 1998-05-22 2006-09-15 Ottawa Health Research Inst METHODS AND PRODUCTS FOR INDUCING MUCOSA IMMUNITY
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1150710B1 (en) * 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (en) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 Flexible metal laminate and production method thereof
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US8834900B2 (en) * 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
MXPA05004588A (en) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR20100018029A (en) * 2004-07-18 2010-02-16 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
FR2881050B1 (en) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa DCCHOL IN THE NEW-NES
CN101268101A (en) * 2005-07-07 2008-09-17 科利制药集团公司 Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
MX2009003398A (en) 2006-09-27 2009-08-12 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity.
WO2010111292A1 (en) 2009-03-23 2010-09-30 Nanirx, Inc. Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE
FR2732895B1 (en) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (en) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc USE OF AN AMPHIPATHIC COMPOUND TO ADJUST A SUBUNIT VACCINE
FR2783170B1 (en) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc IMMUNOSTIMULATING EMULSION
JP2002537102A (en) * 1999-02-26 2002-11-05 カイロン コーポレイション Microemulsion with adsorbed polymer and fine particles
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
MXPA02002107A (en) * 1999-08-27 2003-08-20 Inex Pharmaceuticals Corp Compositions for stimulating cytokine secretion and inducing an immune response.
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
FR2814958A1 (en) 2002-04-12
PT1326635E (en) 2005-08-31
WO2002028428A3 (en) 2003-02-20
PT1326636E (en) 2007-02-28
ATE350057T1 (en) 2007-01-15
US20030190326A1 (en) 2003-10-09
WO2002028428A2 (en) 2002-04-11
AU2001295673A1 (en) 2002-04-15
ES2240526T3 (en) 2005-10-16
DE60125797T2 (en) 2007-12-06
EP1326636B1 (en) 2007-01-03
CA2424836A1 (en) 2002-04-11
DE60110822D1 (en) 2005-06-16
EP1326636A2 (en) 2003-07-16
US20050118188A1 (en) 2005-06-02
EP1326635A2 (en) 2003-07-16
DE60125797D1 (en) 2007-02-15
WO2002028427A2 (en) 2002-04-11
US20040038922A1 (en) 2004-02-26
ES2275738T3 (en) 2007-06-16
FR2814958B1 (en) 2003-03-07
ATE295180T1 (en) 2005-05-15
EP1326635B1 (en) 2005-05-11
CY1105943T1 (en) 2011-04-06
DK1326636T3 (en) 2007-04-30
WO2002028427A3 (en) 2003-03-20
DE60110822T2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
AU2001295671A1 (en) Pharmaceutical composition for immunisation against aids
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
ES2140076T3 (en) VACCINES CONTAINING A SAPONIN AND A STEROL.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
WO2001060402A3 (en) Proteosome influenza vaccine
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
WO2002080965A3 (en) Vaccine composition
EP0634937A1 (en) VACCINES CONTAINING NON - IONIC TENSIO ACTIVE VESICLES.
WO2001034801A3 (en) Recombinant gelatin in vaccines
EE200200507A (en) Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing it, Preparation and Therapeutic Use of MVA
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
EP0745387A3 (en) Adjuvants for viral vaccines
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
ES2137310T3 (en) VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION.
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2003059385A3 (en) Hiv vaccine and method of use
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
AU5499996A (en) Chlamydia vaccines
WO2003049765A3 (en) Enveloped virus vaccine and method for production
WO1998040097A3 (en) Bovine respiratory and enteric coronavirus as a vaccine
EP0955366A4 (en) Antigenic protein originating in malassezia
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
AU2001239180A1 (en) Immunomodulatory effective compositions, methods for the production thereof and their use
WO2004050692A3 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production